Annexon, Inc. has disclosed a noteworthy update in its ownership structure through a recent filing. FMR LLC, a prominent investment management firm, now holds 13.9% of the company's common stock. This development is significant as it may impact the strategic direction of Annexon, particularly in the competitive landscape of pharmaceutical preparations.
Founded in 2012 and based in Brisbane, California, Annexon operates within the pharmaceutical preparations sector, classified under SIC 2834. The company is publicly traded on the Nasdaq under the ticker symbol ANNX. The recent filing reflects the company's ongoing efforts to attract investment, which is crucial for its growth and development in the pharmaceutical industry.
The Schedule 13G/A filing, submitted on November 5, 2026, details that FMR LLC beneficially owns approximately 26,288,999.68 shares of Annexon, indicating a significant investment. The filing states, "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies." This ownership stake positions FMR LLC as a substantial player in Annexon's future.
FMR LLC's increased stake may influence various stakeholders, including shareholders, management, and potential investors. The filing also notes that Abigail P. Johnson, a key figure in FMR LLC, holds a directorship and serves as the Chairman and CEO of the firm. Her involvement could lead to strategic insights and decisions that may benefit Annexon moving forward.
The filing does not specify the next steps following this ownership change. However, it highlights the importance of FMR LLC's role in the company and the potential implications for Annexon's strategy and operations in the pharmaceutical preparations market.